JP7703513B2 - 抗ガレクチン９抗体と化学療法剤の組合せがん治療 - Google Patents

抗ガレクチン９抗体と化学療法剤の組合せがん治療 Download PDF

Info

Publication number
JP7703513B2
JP7703513B2 JP2022506485A JP2022506485A JP7703513B2 JP 7703513 B2 JP7703513 B2 JP 7703513B2 JP 2022506485 A JP2022506485 A JP 2022506485A JP 2022506485 A JP2022506485 A JP 2022506485A JP 7703513 B2 JP7703513 B2 JP 7703513B2
Authority
JP
Japan
Prior art keywords
galectin
antibody
subject
dose
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022506485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543780A (ja
JP2022543780A5 (enExample
Inventor
昌平 小出
ミラー，ジョージ
明子 小出
チェン，リンシアオ
フィリポビッチ，アレクサンドラ
エレンコ，エリック
ボレン，ジョセフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Puretech LYT Inc
Original Assignee
Puretech LYT Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/031181 external-priority patent/WO2020223702A1/en
Application filed by Puretech LYT Inc filed Critical Puretech LYT Inc
Publication of JP2022543780A publication Critical patent/JP2022543780A/ja
Publication of JP2022543780A5 publication Critical patent/JP2022543780A5/ja
Application granted granted Critical
Publication of JP7703513B2 publication Critical patent/JP7703513B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022506485A 2019-08-01 2020-08-03 抗ガレクチン９抗体と化学療法剤の組合せがん治療 Active JP7703513B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962881894P 2019-08-01 2019-08-01
US62/881,894 2019-08-01
PCT/US2020/031181 WO2020223702A1 (en) 2019-05-01 2020-05-01 Anti-galectin-9 antibodies and uses thereof
USPCT/US2020/031181 2020-05-01
PCT/US2020/044777 WO2021022256A1 (en) 2019-08-01 2020-08-03 Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics

Publications (3)

Publication Number Publication Date
JP2022543780A JP2022543780A (ja) 2022-10-14
JP2022543780A5 JP2022543780A5 (enExample) 2023-08-10
JP7703513B2 true JP7703513B2 (ja) 2025-07-07

Family

ID=74229293

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506485A Active JP7703513B2 (ja) 2019-08-01 2020-08-03 抗ガレクチン９抗体と化学療法剤の組合せがん治療

Country Status (7)

Country Link
US (1) US20220332832A1 (enExample)
EP (1) EP4007640A4 (enExample)
JP (1) JP7703513B2 (enExample)
CN (1) CN114502241B (enExample)
AU (1) AU2020319899B2 (enExample)
CA (1) CA3149324A1 (enExample)
WO (1) WO2021022256A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024519449A (ja) * 2021-04-30 2024-05-14 ピュアテック・エル・ワイ・ティ・インコーポレイテッド がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084553A1 (en) 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
CN119033928A (zh) * 2019-05-01 2024-11-29 纽约大学 抗半乳糖凝集素-9抗体及其用途
AU2022266821A1 (en) * 2021-04-30 2023-11-09 Puretech Lyt, Inc. Anti-galectin-9 antibodies and therapeutic uses thereof
CN113624965B (zh) * 2021-08-05 2024-02-09 中国人民解放军军事科学院军事医学研究院 N蛋白特异性IgG4在甄别新型冠状病毒感染者和疫苗接种者中的应用
WO2023056461A1 (en) * 2021-10-01 2023-04-06 Puretech Lyt, Inc. Anti-galectin-9 antibodies and therapeutic uses thereof
CN119286974A (zh) * 2024-12-12 2025-01-10 南方医科大学南方医院 一种晚期结直肠癌靶向治疗预测模型的构建系统
CN120585880B (zh) * 2025-08-07 2025-12-09 四川大学华西医院 一种用于预防和/或治疗前列腺癌的联合用药物，其用途及药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505018A (ja) 2013-01-11 2016-02-18 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法
WO2019084553A1 (en) 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3021970B1 (fr) * 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
CA2954678A1 (en) * 2014-07-14 2016-01-21 The Council Of The Queensland Institute Of Medical Research Galectin immunotherapy
US11254738B2 (en) * 2016-09-07 2022-02-22 The Governing Council Of The University Of Toronto Banting Institute Synthetic antibodies against VEGF and their uses
JP2020535119A (ja) * 2017-09-13 2020-12-03 ファイヴ プライム セラピューティクス インク 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ−１抗体組合せ併用療法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505018A (ja) 2013-01-11 2016-02-18 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法
WO2019084553A1 (en) 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Alvaro DE MINGO PULIDO et al.，"TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer"，Cancer Cell，2018年01月，Vol. 33, No. 1，p.60-74.e6，DOI: 10.1016/j.ccell.2017.11.019

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024519449A (ja) * 2021-04-30 2024-05-14 ピュアテック・エル・ワイ・ティ・インコーポレイテッド がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用

Also Published As

Publication number Publication date
EP4007640A1 (en) 2022-06-08
JP2022543780A (ja) 2022-10-14
CN114502241A (zh) 2022-05-13
AU2020319899A1 (en) 2022-02-24
US20220332832A1 (en) 2022-10-20
AU2020319899B2 (en) 2026-04-09
CA3149324A1 (en) 2021-02-04
EP4007640A4 (en) 2023-10-04
CN114502241B (zh) 2026-04-03
WO2021022256A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
AU2020319899B2 (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
JP7581238B2 (ja) 抗ガレクチン９抗体およびその使用
US20240043543A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
WO2022093841A1 (en) Anti-galectin-9 antibodies and uses thereof in the treatment of ocular melanoma
US20240109968A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
US20240182583A1 (en) Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
JP2024519450A (ja) 抗ガレクチン－９抗体及びその治療的使用
TW202502382A (zh) 治療組合及其用途和治療方法
HK40074716A (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
WO2025085792A1 (en) Treatment of hematological malignancies with antibodies inhibiting galectin-9
HK40069657B (en) Anti-galectin-9 antibodies and uses thereof
HK40069657A (en) Anti-galectin-9 antibodies and uses thereof
HK40108543A (en) Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
WO2023056461A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
WO2025141589A1 (en) Treatment of cancer with anti-ilt3 antibodies
HK40109234A (en) Methods and compositions for treating cancer
CN117580589A (zh) 在癌症疗法中使用的抗半乳糖凝集素-9抗体和化疗剂的组合
HK40098226A (en) Anti-galectin-9 antibodies and uses thereof in the treatment of ocular melanoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230802

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250625

R150 Certificate of patent or registration of utility model

Ref document number: 7703513

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150